Corcept Therapeutics Faces Major Securities Litigation Over Relacorilant Regulatory Claims

Hagens Berman has filed a securities class action lawsuit against Corcept Therapeutics ($CORT), accusing the biopharmaceutical company of systematically misleading investors regarding the regulatory viability of its flagship drug candidate relacorilant. The lawsuit centers on allegations that Corcept made public statements claiming the drug was "approaching approval," while simultaneously receiving multiple warnings from the FDA that clinical data was insufficient to support the application. The dramatic collapse came on December 31, 2025, when Corcept received a Complete Response Letter from regulators, triggering a catastrophic stock decline that erased approximately $3.6 billion in market value. Investors alleging damages have until April 21, 2026, to file as lead plaintiffs in the action.

The Regulatory Breakdown and Stock Collapse

The lawsuit alleges a significant disconnect between Corcept's public messaging and private regulatory communications. According to the complaint, the FDA had warned the company multiple times throughout the regulatory review process that the clinical data supporting relacorilant was inadequate for approval. Despite these internal warnings, Corcept publicly maintained an optimistic stance, characterizing the drug as nearing approval status in investor communications and earnings calls.

The financial impact was severe and immediate:

• Stock price before CRL: $70.20 per share
• Stock price after CRL: $34.80 per share
• Percentage decline: Approximately 50.4%
• Market capitalization erased: $3.6 billion
• CRL issuance date: December 31, 2025

A Complete Response Letter from the FDA indicates that an application cannot be approved in its current form and typically requires substantial additional clinical or manufacturing data. This outcome represents one of the most significant regulatory setbacks in recent biotech history, particularly given the company's pre-CRL public positioning.

Market Context and Industry Implications

The Corcept situation reflects broader volatility and risks inherent in biopharmaceutical development, where regulatory approval remains unpredictable despite years of clinical work and investor capital deployment. Relacorilant was positioned as Corcept's lead asset and primary growth driver, making the failed approval attempt a watershed moment for the company's strategic prospects.

The biotech sector has experienced heightened regulatory scrutiny in recent years, with the FDA maintaining rigorous standards for clinical efficacy and safety. The Complete Response Letter to Corcept aligns with this trend, though the specific allegations in the lawsuit—that executives knew about deficiencies while maintaining optimistic public statements—would, if proven, constitute securities fraud.

Key contextual factors include:

• Sector backdrop: Biotech companies routinely face binary risk events tied to regulatory decisions
• Investor expectations: Market participants typically price in meaningful approval probability based on company guidance
• Communication standards: Public companies must disclose material risks and not misrepresent regulatory feedback or approval likelihood
• Precedent: Previous biotech securities cases have resulted in substantial settlements when evidence of misleading statements is established

The litigation also serves as a cautionary tale for biotech investors regarding due diligence around regulatory risk communication and the importance of parsing language carefully in investor presentations.

Investor Implications and Forward-Looking Concerns

For shareholders and potential claimants, the implications are multifaceted. Corcept shareholders who purchased stock at or near peak valuations between the alleged misleading statements and the December 31 CRL announcement face substantial losses. The lawsuit provides a mechanism for recovering damages, though the timeline and ultimate settlement or judgment amount remain uncertain.

Beyond individual investor recovery, the litigation raises broader questions about Corcept's operational viability and strategic direction. Key considerations for stakeholders include:

• Pipeline depth: Whether Corcept has other candidates with meaningful commercial potential
• Financial runway: Cash position and burn rate given the loss of relacorilant revenue projections
• Management accountability: Potential leadership changes or board-level consequences
• Regulatory path forward: Whether relacorilant can be revived through additional trials or if it will be abandoned
• Settlement risk: Potential financial obligations from the securities class action

The April 21, 2026 lead plaintiff deadline represents a critical juncture for affected investors seeking to participate in the litigation. Institutional investors and individual shareholders with substantial losses may seek to serve as lead plaintiffs, which typically involves greater involvement in the case management and settlement negotiations.

From a market dynamics perspective, the Corcept situation underscores the hazards of regulatory binary events in biotech investing. Even companies with substantial clinical progress and experienced management teams face unpredictable outcomes at the FDA review stage. The alleged gap between private knowledge and public statements—if substantiated—suggests potential governance or compliance failures that may warrant scrutiny at other biotech firms with concentrated pipelines.

Conclusion and Path Forward

The Hagens Berman lawsuit against Corcept Therapeutics represents a high-stakes securities action with potential implications extending beyond the company itself. The allegations of regulatory misrepresentation, coupled with the severe stock decline and substantial market value destruction, create a compelling basis for litigation. As the April 21, 2026 lead plaintiff deadline approaches, affected investors must carefully evaluate their options and the strength of their claims.

For Corcept, the litigation compounds an already challenging situation following the relacorilant Complete Response Letter. The company faces simultaneous pressures: rebuilding investor confidence, determining the path forward for its lead asset, and managing financial obligations stemming from the securities action. The outcome of this litigation will likely influence not only Corcept's near-term valuation but also broader market expectations around regulatory communication transparency within the biopharmaceutical sector.